Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-center, Open-label, Multiple Ascending Dosage-ranging Cohort (MAD) Study in Early, Untreated or Stably Treated Subjects With Parkinson's Disease (PD), to Determine the Safety, Tolerability and Pharmacokinetics (PK) of Injections of SER-214 Administered Subcutaneously Once a Week for Two Weeks After 0-2 Weeks of Dose Titration

NCT02579473 is registered in ClinicalTrials.gov with Serina Therapeutics as lead sponsor.

NCT NCT02579473
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02579473 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-center, Open-label, Multiple Ascending Dosage-ranging Cohort (MAD) Study in Early, Untreated or Stably Treated Subjects With Parkinson's Disease (PD), to Determine the Safety, Tolerability and Pharmacokinetics (PK) of Injections of SER-214 Administered Subcutaneously Once a Week for Two Weeks After 0-2 Weeks of Dose Titration
Lead sponsor
Serina Therapeutics
Phase
Phase 1
Overall status
Unknown status
Start date
January 31, 2016
Completion date
December 31, 2023
Enrollment
20 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

parkinson's disease